Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience
Am J Clin Pathol · 2026
DOI: 10.1093/ajcp/aqaf128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Am J Clin Pathol, 2026. Verfasst von Robert M Humble und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: In Situ Hybridization, Fluorescence, Prostatic Neoplasms, Transcriptional Regulator ERG, Adenocarcinoma. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
Objective
ERG gene fusions are present in up to 60% of localized prostate cancer and up to 45% of metastatic prostate cancer. Fluorescence in situ hybridization (FISH) assays can detect the vast majority of ERG gene fusions and help confirm prostatic origin. We reviewed clinical ERG FISH assays performed at our tertiary institution by our in-house consult services between 2016 and 2024 where prostatic adenocarcinoma was in the differential diagnosis.
Methods
We summarized clinical information, immunohistochemistry results (including ERG), and ERG FISH status in a cohort of 15 consecutive clinical ERG FISH assays performed for 14 patients in whom a diagnosis of prostatic adenocarcinoma was considered.
Results
ERG FISH testing was positive in 7 of 15 (46.7%) cases, indeterminate in 1 of 15 (6.7%) cases, and negative in 7 of 15 (46.7%) cases. In 6 of 7 (85.7%) positive cases, the ERG FISH-positive result supported prostatic origin in metastatic (n = 4) or undifferentiated (n = 2) disease.
Conclusions
Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
- Center for Translational Pathology, Ann Arbor, MI, United States.
- Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, United States.
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI, United States.
- Howard Hughes Medical Institute, Ann Arbor, MI, United States.
ORCID-Profile: Robert M Humble
Zitieren
APA
Humble, R. M., Paturu, R., Xiao, H., Yang, C., Iwata-Otsubo, A., Dhanasekaran, S. M., Brown, N. A., Betz, B. L., Kim, A. S., Myers, J. L., Chinnaiyan, A. M., Shao, L., & Mehra, R. (2026). Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaf128
Vancouver
Humble RM, Paturu R, Xiao H, Yang C, Iwata-Otsubo A, Dhanasekaran SM, et al. Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience. Am J Clin Pathol. 2026. doi:10.1093/ajcp/aqaf128
BibTeX
@article{Humble2026,
author = {Humble, Robert M and Paturu, Radha and Xiao, Hong and Yang, Chen and Iwata-Otsubo, Aiko and Dhanasekaran, Saravana M and Brown, Noah A and Betz, Bryan L and Kim, Annette S and Myers, Jeffrey L and Chinnaiyan, Arul M and Shao, Lina and Mehra, Rohit},
title = {Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience},
journal = {Am J Clin Pathol},
year = {2026},
doi = {10.1093/ajcp/aqaf128}
}
EUVIMED